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A peptide-based enzyme-linked immunosorbent assay
(ELISA) can be used for retrospective serosurveillance of
severe acute respiratory syndrome (SARS) by helping
identify undetected chains of disease transmission. The
assay was developed by epitope mapping, using synthetic
peptides from the spike, membrane, and nucleocapsid pro-
tein sequences of SARS-associated coronavirus. The new
peptide ELISA consistently detected seroconversion by
week 2 of onset of fever, and seropositivity remained
through day 100. Specificity was 100% on normal blood
donor samples, on serum samples associated with infec-
tion by other pathogens, and on an interference panel. The
peptide-based test has advantages of safety, standardiza-
tion, and automation over previous immunoassays for
SARS. The assay was used for a retrospective survey of
healthy healthcare workers in Taiwan who treated SARS
patients. Asymptomatic seroconversions were detected in
two hospitals that had nosocomial disease.
R
etrospective surveillance for infection is an important
means to screen for and interrupt undetected chains of
disease transmission. Such surveillance may be key to
tracking the severe acute respiratory syndrome–associated
coronavirus (SARS-CoV) because mild and asymptomatic
cases of SARS-CoV infection that do not meet the World
Health Organization’s case definition (1) have been identi-
fied by immunoassays (2–4), and SARS-CoV–like viruses
have been isolated from wild mammals (5). SARS-CoV
may have persisted over the summer in previously affect-
ed areas in such difficult-to-recognize reservoirs (6). The
reemergence of SARS in the city of Guangzhou of the
Guangdong Province of China in December 2003 and
January 2004 (7) is evidence that an unknown reservoir
exists and signals the need for continued surveillance with
laboratory testing.
The current laboratory methods for identifying SARS
are not ideal tools for use in retrospective mass
screening. Reverse transcription–polymerase chain reac-
tion  (RT-PCR) for detecting viral RNA is the most sensi-
tive method for early identification of SARS. However,
viral load rapidly declines beginning 9 or 10 days after dis-
ease onset (8–10). Moreover, RT-PCR requires sophisticat-
ed equipment and high laboratory quality-assurance
standards (11,12). Identifying seroconversion to SARS-
CoV by immunoassay also is a definitive criterion for lab-
oratory determination of SARS (13), and seroconversion is
the preferred standard for retrospectively detecting SARS-
CoV infection (14). SARS immunoassays include the
enzyme-linked immunosorbent assay (ELISA) or Western
blot with antigen from whole virus or various recombinant
proteins, a cumbersome immunofluorescence assay (IFA)
using whole virus fixed on glass, and methods to deter-
mine neutralizing antibodies (10,11). Immunoglobulin (Ig)
G to SARS-CoV, detected by these immunoassays, begins
to rise sharply by day 11 after onset of symptoms. Virtually
all SARS patients show virus-specific antibody by week 3,
and anti–SARS-CoV IgG persists through day 100
(8,10,15). Although any of these immunoassays can pro-
vide a definitive laboratory finding, all but the recombi-
nant tests require biosafety level 3 to contain the virus or
are time-consuming to perform, have not been well-stan-
dardized, are of unknown specificities, and would be diffi-
cult to adapt to large-scale manufacture. Improving
laboratory methods for the large-scale serologic surveil-
lance of SARS, particularly in the presence of other respi-
ratory illnesses, and standardization of diagnostic assays
are key priorities for controlling SARS (16). In this report,
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Beginning in April 2003, delay in recognizing SARS
cases and in implementing isolation procedures led to sev-
eral nosocomial clusters of SARS-CoV transmission in
healthcare facilities in Taiwan (17,18). The results from a
retrospective serologic survey by the peptide ELISA of
healthcare workers from facilities affected by nosocomial
outbreaks are presented as a working example. 
Materials and Methods
Synthetic Peptide ELISA
We developed an ELISA for SARS that has synthetic
peptide antigens as the solid-phase immunosorbent. Over
200 overlapping peptides, deduced from the Tor2 SARS-
CoV genomic sequence (19), were synthesized as candi-
date antigens from the spike (S), membrane (M), and
nucleocapsid (N) proteins. Candidate immunodominant S,
M, and N peptides were selected and refined on the basis
of serologic reactivities to a panel of serum samples from
13 patients clinically diagnosed with SARS at National
Taiwan University Hospital in Taipei and the
Xiaotangshan SARS Emergency Hospital in Beijing (20).
Epitope mapping by serologic validation has been
described for the development of peptide-based ELISA
tests for HIV, hepatitis C virus, and foot-and-mouth dis-
ease virus (21–23). For the peptide-based SARS ELISA,
wells of microtiter plates were coated with 2 µg/mL of a
mixture of the S, M, and N protein–derived peptides, and
serologic reactivities were determined by a standard
ELISA procedure as previously described (23), except
that the detector was horseradish peroxidase–conjugated
goat anti-human IgG, and the chromaphore was 3,3′,5,5′-
tetramethylbenzidine (TMB). In brief, serum samples,
including two normal human samples provided as nonre-
active controls, were diluted 1:20 in phosphate-buffered
saline with carrier proteins and preservative. The diluted
serum samples were reacted to the peptide-coated
microtiter wells for l h at 37°C. Plates were washed 6
times, reacted to the antibody conjugate, again washed 6
times, and reacted to TMB; reactivity was then deter-
mined by A450. Assay results were obtained within 3 h.
Results were scored on the basis of the signal/cutoff (S/C)
ratio, and cutoff absorbance was determined from the
mean of the two controls plus 6 standard deviations
(SD) from the distribution of normal human samples
(Figure 1).
Serum Panels
Seroconversion panels were collected as serial serum
samples from SARS patients at National Taiwan
University Hospital in the course of treatment. These pan-
els tested positive for seroconversion by IFA (24) and are
used here to evaluate analytical sensitivity.
A panel of 69 serum samples from convalescent SARS
patients were provided by the Center for Disease Control,
Department of Health, Taiwan, to evaluate diagnostic sen-
sitivity. These serum specimens were confirmed for
SARS-CoV infection clinically by the World Health
Organization diagnostic criteria (1) and serologically by
whole virus–based ELISA and IFA; some specimens were
also confirmed by RT-PCR (24). Samples were drawn with
appropriate timing for serologic reactivity (7–25 weeks
after onset of symptoms). Apanel of 1,390 plasma samples
collected from random blood donors in Florida before
2001 was obtained from the Gulf Coast Regional Blood
Center (Houston, TX) for specificity evaluation.
Additional specificity studies were conducted with
serum that had serologic reactivities for bloodborne
pathogens (HIV-1, HIV-2, hepatitis C virus, HTLV 1/II,
and syphilis) obtained by United Biomedical Inc. before
2000 from various U.S. sources, an interference panel sup-
plied by Boston Biomedica Inc. (Boston, MA) of serum
samples with interference substances commonly found in
processed clinical samples (EDTA, acid citrate dextrose,
and citrate phosphate dextrose with adenine), and serum
supplied by National Taiwan University Hospital from
patients associated with typical and atypical respiratory
pathogens other than SARS-CoV (influenza, rubella,
cytomegalovirus, Epstein-Barr virus, and Mycoplasma
pneumoniae). Serum samples were collected from healthy
healthcare workers after interviews to confirm lack of
signs and symptoms of SARS  including fever, respiratory
symptoms, and diarrhea.
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Figure 1. Distribution of tested specimens. Signal/cutoff (S/C) dis-
tribution of Center for Disease Control (Taiwan) SARS (severe
acute respiratory syndrome) serum panel and blood donor serum
panel. The mean signal/cutoff (S/C) ratio for the SARS samples
was 8.08. The mean S/C for the 1,390 normal human plasma was
0.28.Results
Sensitivity
The peptide-based ELISA was evaluated for sensitivity
to seroconversion on eight seroconversion panels obtained
from National Taiwan University Hospital (Figure 2,
Table 1). In patient 1, seroconversion was detected by day
11 with an A450 of 1.638. Absorbance remained at >2 at day
97. In patient 2, from whom blood was drawn on days 0,
6, 16, 27, and 116 (no samples were collected from day 6
to day 16), seroconversion was apparent on day 16 after
the onset of fever. On day 116, the A450 remained >3. In
five of the other six seroconversion panels, from acute to
convalescent phases, seropositivity was observed by days
8 to 12, and by day 16 in patient 6, from whom serum had
not been collected from days 6 to 16 (Figure 2). The pep-
tide-based ELISAshowed an analytical sensitivity to earli-
est time of detection by week 2 and for duration of
detection beyond day 100. The seroreactivities of patients
3 to 8 were also evaluated by a standard IFA method (24)
for comparison. Seroconversion was detected in all six
patients by the IFA method within 2 days of the peptide
ELISA (data not shown). 
The diagnostic sensitivity of the peptide ELISA was
100% on a panel of 69 convalescent-phase serum samples
from SARS patients provided as a reference panel by the
Center for Disease Control, Department of Health, Taiwan.
These sera, confirmed for SARS by diagnostic and sero-
logic criteria, displayed a mean S/C ratio of 8.08 (Figure 1). 
Specificity
The specificity of the peptide-based SARS ELISA was
tested on plasma obtained before 2001 from 1,390 random
Florida blood donors (Gulf Coast Regional Blood Center,
Houston, TX). These normal plasma samples with a pre-
sumed zero seroprevalence rate gave a mean A450 of 0.074
± 0.0342 (SD). Subsequently, the cutoff value for the pep-
tide-based assay was set as the mean A450 for duplicate
nonreactive controls plus 0.279 (based on 6 SDs from the
mean for these 1,390 normal plasma samples). The distri-
bution of the S/C ratio for the blood bank samples is plot-
ted in Figure 1 with the mean S/C ratio of 0.28. None
showed positive reactivity, for a specificity on the normal
samples of 100% (Table 2). 
The peptide ELISA was further evaluated for specifici-
ty with a pre-2000 collection of serum samples from
patients with seropositivities for bloodborne pathogens
such as HIV-1, HIV 2, hepatitis C virus, HTLV 1/II, and
syphilis (various U.S. sources), and with normal serum
samples spiked with interference substances heparin,
EDTA, ACD, and CPDA-1 (Boston Biomedica). The 52
samples with seroreactivities for the pathogens all tested
negative by the peptide-based SARS ELISA, as did the 41-
sera interference panel (Table 2).
The peptide ELISA was evaluated for specificity on
serum samples drawn from patients associated with typical
and atypical respiratory pathogens other than SARS-CoV
(National Taiwan University Hospital). These included
samples from 1) 10 patients naturally infected with influen-
za (two sequential bleeds per influenza patient), 2) 10
patients with rubella, 3) 8 patients with cyto-megalovirus
infection, 4) 9 patients with Epstein-Barr virus, 5) 5
patients infected with Mycoplasma pneumoniae, a
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Figure 2. Time of seroconversion from onset of fever for patients
infected with severe acute respiratory syndrome–associated coro-
noavirus. Cutoff absorbance shown by dotted line. 
Table 1. Sensitivity of peptide-based SARS-CoV ELISA from two 
patients at NTU
a
Patient/day A450nm   S/C ratio 
SARS patient 1     
Day 0  0.119  0.44 
Day 11  1.638  6.09 
Day 17  2.447  9.10 
Day 38  2.749  10.22 
Day 97  2.600  9.67 
SARS patient 2     
Day 0  0.068  0.25 
Day 6  0.163  0.61 
Day 16  0.345  1.28 
Day 27  1.212  4.51 
Day 116  !3.000  !9.40 
aSARS, severe acute respiratory syndrome; CoV, coronavirus; ELISA, 
enzyme-linked immunosorbent assay; S/C = signal/cutoff ratio; NTU, 
National Taiwan University.bacterial agent for atypical pneumonia, and 6) pre- and
postvaccine blood samples from 16 patients given influen-
za vaccine. All samples were tested in duplicate. The site-
specific antigens of the peptide SARS-CoV ELISA were
free of cross-reactivities to the other respiratory pathogens
(Table 2).
Serologic Survey of Healthcare Workers
A prospective study was performed to determine
asymptomatic infection among primary healthcare work-
ers in hospitals that treated SARS patients. We collected
serum samples from 623 healthcare workers without
symptoms, not all of whom were in direct contact with
SARS patients, who agreed to be tested for antibody to
SARS-CoV at Ho Ping, Yang Ming, En Chu Kong, and
Hsin Tai Hospitals, approximately 4 weeks after the out-
breaks were recognized. Ho Ping and Yang Ming Hospitals
had admitted SARS patients before the recognition of
SARS and before healthcare workers had implemented
control measures. Subsequently, these facilities experi-
enced transmission to healthcare workers. The En Chu
Kong and Hsin Tai facilities admitted patients once control
measures had been implemented. Neither of these hospi-
tals recorded transmission of SARS to healthcare workers. 
ELISA detected three cases out of 383 samples from
Ho Ping and one case in 50 blood samples from nursing
aides at Yang Ming. These four positive samples, indica-
tive of asymptomatic infection, were confirmed for
seropositivity by IFA. None of the 190 serum samples
from the two hospitals without nosocomial infection dis-
played seroconversion.
Discussion
A convenient ELISA to detect IgG to SARS-CoV,
based on site-specific synthetic antigens taken from the S,
M, and N proteins of the virus, has high specificity. No
cross-reactivity was detected in samples associated with
common non-coronavirus respiratory pathogens. In addi-
tion, the lack of detectable reactivities among the 1,390
U.S. blood donors supports a specificity for the assay to
distinguish SARS-CoV infection from infection by other
human coronaviruses. The presence of anti-coronavirus
antibodies among a U.S. population of this size is strongly
anticipated because an incidence as high as 8% for OC43
and 229E respiratory infections has been observed, even
among healthy young adults (25).
The new peptide-based ELISAis equivalent in sensitiv-
ity to other immunoassays for SARS and can be detected
after day 100. The synthetic antigens provide the advan-
tages of high standardization, freedom from biohazard,
and ease of scale-up production. Moreover, testing by the
ELISA format can be readily automated for large-scale
screening. The highly specific peptide-based SARS anti-
body test is a convenient means to carry out widespread
retrospective surveillance, such as that now being pro-
posed for China to trace hotspots of persons carrying anti-
bodies to SARS-CoVand to track the origins of the disease
(26).
A preliminary survey with the peptide ELISA detected
asymptomatic clusters of seroconversion among exposed
healthcare workers in two Taiwan hospitals that also had
nosocomial disease. In contrast, no seroconversion was
found among the exposed healthcare workers from two
hospitals that had no apparent disease transmission to
healthcare workers. The finding of asymptomatic seropos-
itive persons indicates that the test will be useful in larger
retrospective surveillance studies, which are needed to
fully define the epidemiology and spectrum of disease.
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Table 2. Sensitivity and specificity of peptide-based ELISA
a
Source of samples  Total no.  ELISA  ELISA– 
Blood donors (Gulf Coast Regional Blood Bank, USA)  1,390  0  1,390 
Blood-transmitted pathogen panel (various blood banks, USA)  52  0  52 
Interference panel (BBI)  41  0  41 
Confirmed SARS (TW CDC)  69  69  0 
Influenza patients (NTU)  10  0  10 
Influenza vaccinees (NTU)  16  0  16 
Rubella patients (NTU)  10  0  10 
EBV patients (NTU)  9  0  9 
Mycoplasma (NTU)  5  0  5 
CMV patients (NTU)  8  0  8 
aELISA, enzyme-linked immunosorbent assay; NTU, National Taiwan University; BBI, Boston Biomedica Inc (Boston, MA); TW CDC, Taiwan Center for 
Disease Control; CMV, cytomegalovirus; EBV, Epstein-Barr virus. 
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